Latest Articles

Publication Date
The effect of norethisterone acetate on the uterine telocytes, immune cells and progesterone receptors in albino rats - Nature.com

The effect of norethisterone acetate on the uterine telocytes, immune cells and progesterone receptors in albino rats Nature.com

Published: March 15, 2025, 2:19 p.m.
The effect of norethisterone acetate on the uterine telocytes, immune cells and progesterone receptors in albino rats.

This study is the first attempt to examine the effects of NETA on immune cells and telocytes. The results of this study form an important knowledge base for the development …

Published: March 15, 2025, midnight
Retraction Note: The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial - Reproductive Health

Retraction Note: The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial Reproductive Health

Published: March 9, 2025, 9:57 p.m.
Retraction Note: The comparison of two different protocols ultra-long versus medroxyprogesterone acetate in women with ovarian endometriosis: a prospective randomized controlled trial.

Published: March 9, 2025, midnight
Primary Low-Grade Endometrial Stromal Sarcoma of the Ovary Arising From Endometriosis: A Case Report.

Low-grade endometrial stromal sarcoma (LGESS) is a rare mesenchymal tumor of female genital tract malignancies. While it primarily arises in the uterus, extrauterine cases, including those originating in the ovary, …

Published: Feb. 23, 2025, midnight
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system.

Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.

Published: Jan. 31, 2025, midnight
SAHPRA Issues Warning on Meningioma Risk with Medroxyprogesterone Acetate Use, Updates Product Information - Devdiscourse

SAHPRA Issues Warning on Meningioma Risk with Medroxyprogesterone Acetate Use, Updates Product Information Devdiscourse

Published: Jan. 17, 2025, 4:01 p.m.
Selective progesterone receptor modulators for the treatment of dysmenorrhea: an update.

Dysmenorrhea is a painful symptom associated with uterine contractions and menstrual bleeding and is treated by administering analgesic drugs. Since progesterone receptors (PRs) have a major role in regulating uterine …

Published: Jan. 14, 2025, midnight
Recent Trends in Medical Management of Endometriosis.

Endometriosis affects about 10 percent women in the reproductive age group globally and approximately 42 million in India. Managing the patient's pain symptoms associated with endometriosis appears to be the …

Published: Dec. 26, 2024, midnight
Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data.

Medroxyprogesterone acetate (MPA), a synthetic progestogen, is extensively used for the treatment of various conditions, including contraception, irregular menstruation, functional uterine bleeding, and endometriosis. However, like all pharmaceutical agents, MPA …

Published: Dec. 11, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!